218 related articles for article (PubMed ID: 11233659)
1. Infliximab for the treatment of orofacial Crohn's disease.
Mahadevan U; Sandborn WJ
Inflamm Bowel Dis; 2001 Feb; 7(1):38-42. PubMed ID: 11233659
[TBL] [Abstract][Full Text] [Related]
2. Treatment-resistant lingual Crohn's disease disappears after infliximab.
Brunner B; Hirschi C; Weimann R; Seibold F
Scand J Gastroenterol; 2005 Oct; 40(10):1255-9. PubMed ID: 16265783
[TBL] [Abstract][Full Text] [Related]
3. Rapid response of severe refractory metastatic Crohn's disease to infliximab.
Miller AM; Elliott PR; Fink R; Connell W
J Gastroenterol Hepatol; 2001 Aug; 16(8):940-2. PubMed ID: 11555113
[TBL] [Abstract][Full Text] [Related]
4. [Successful primary infliximab treatment of orofacial Crohn's disease without gastrointestinal manifestation].
Jung BY; Lee SH; Chung SK; Lee CK; Lee TH; Chung IK; Kim SJ; Cho HD
Korean J Gastroenterol; 2012 Jun; 59(6):437-40. PubMed ID: 22735878
[TBL] [Abstract][Full Text] [Related]
5. Infliximab for the treatment of hidradenitis suppurativa.
Lebwohl B; Sapadin AN
J Am Acad Dermatol; 2003 Nov; 49(5 Suppl):S275-6. PubMed ID: 14576652
[TBL] [Abstract][Full Text] [Related]
6. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
7. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease].
Holtmann M; Wanitschke R; Helisch A; Bartenstein P; Galle PR; Neurath M
Z Gastroenterol; 2003 Jan; 41(1):11-7. PubMed ID: 12541166
[TBL] [Abstract][Full Text] [Related]
8. [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication].
Lee KM; Kim JS; Shin DH; Cheong JY; Yoo BM; Kim JK; Lee KJ; Hahm KB; Kim JH; Cho SW
Korean J Gastroenterol; 2004 Nov; 44(5):259-66. PubMed ID: 15564805
[TBL] [Abstract][Full Text] [Related]
9. New therapy for orolaryngeal manifestations of Crohn's disease.
Ottaviani F; Schindler A; Capaccio P; Petrone M; Bianchi Porro G
Ann Otol Rhinol Laryngol; 2003 Jan; 112(1):37-9. PubMed ID: 12537056
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
11. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of refractory esophageal Crohn's disease with infliximab.
Fefferman DS; Shah SA; Alsahlil M; Gelrud A; Falchulk KR; Farrell RJ
Dig Dis Sci; 2001 Aug; 46(8):1733-5. PubMed ID: 11508675
[No Abstract] [Full Text] [Related]
13. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
14. An unusual cutaneous manifestation of Crohn's disease.
Weiser JA; Markowitz DM; Husain S; Grossman ME
Skinmed; 2011; 9(3):196-8. PubMed ID: 21675504
[TBL] [Abstract][Full Text] [Related]
15. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
[TBL] [Abstract][Full Text] [Related]
16. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
[TBL] [Abstract][Full Text] [Related]
17. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection.
Campbell S; Ghosh S
Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):191-2. PubMed ID: 11246620
[TBL] [Abstract][Full Text] [Related]
18. Systemic amyloidosis with Crohn's disease treated with infliximab.
Park YK; Han DS; Eun CS
Inflamm Bowel Dis; 2008 Mar; 14(3):431-2. PubMed ID: 17932971
[No Abstract] [Full Text] [Related]
19. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
20. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab.
van Deventer SJ
Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():3-8; discussion 38. PubMed ID: 10597333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
